Alerta

MULTISUBUNIT HERPESVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003586A2

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a herpesvirus. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT HEPACIVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003577A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a hepacivirus. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT RSV, HMPV AND HPIV VACCINES AND THERAPEUTICS

Resumen de: WO2026003578A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT PAPILLOMAVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003579A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of self-assembling immunogenic sequences or a plurality of self-assembling immunogenic sequences each further comprising one or more target sequence, or a combination thereof, wherein each self-assembling immunogenic sequence of the plurality is connected to an adjacent self-assembling immunogenic sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the self-assembling immunogenic sequences of the plurality. Also disclosed are multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises a plurality of self-assembling immunogenic sequence, or a plurality of self-assembling immunogenic sequence each further comprising one or more target sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by one or more cleavage sequence and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the polynucleotide sequence of the plurality. The multisubunit nucleic acid encodes multisubunit peptide.

MRNA BASED CFTR PRECURSOR AND PREPARATION METHOD THEREOF

Resumen de: WO2026003875A1

The present disclosure discloses a messenger ribonucleic acid (mRNA) molecule encoding for a cystic fibrosis transmembrane conductance regulator (CFTR) protein. The mRNA molecule is encoded by SEQ ID No. 25 or a sequence having 95% identity to SEQ ID No. 25.

NANO-FORMULATION FOR CLEARING SENESCENT CELLS, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2026000480A1

A nano-formulation for clearing senescent cells, a preparation method therefor, and use thereof. A gingerenone A-loaded aminated dendritic mesoporous silica nano-formulation is constructed. Dendritic mesoporous silica having a unique central radial pore structure is selected as a drug carrier; the drug carrier is further modified with amino groups, and gingerenone A is loaded onto the aminated dendritic mesoporous silica via non-covalent interactions. The obtained nano-formulation has a uniform particle size, and exhibits the characteristics of high drug loading, high encapsulation efficiency, high biocompatibility, rapid cellular uptake, and low cytotoxicity. Moreover, the nano-formulation can significantly enhance the ability of gingerenone A to clear senescent cells, thereby improving the bioavailability of gingerenone A, and broadening the clinical application of gingerenone A. The nano-formulation has good application prospects in functional foods, pharmaceuticals, and cosmetics.

SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000081A1

Embodiments disclosed herein relate to sulfur-containing lipids. Examples of lipids described herein have a structure of Formula (A) or a pharmaceutically acceptable salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

IONIZABLE LIPIDS COMPRISING CYCLIC MOIETIES FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000083A1

Provided herein are novel sulfur-containing lipids having a structure of Formula (A) or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

IONIZABLE LIPIDS WITH MODIFIED HEAD GROUPS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000082A1

Embodiments described herein are directed to lipids having a structure of Formula (A) or a salt thereof and wherein A is carbon or nitrogen and the head group comprises a moiety of Formula (B). A1 and A2 are, independently, O or S and G1, G2 and G3 are as defined herein. The lipids may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

NITROGEN-CONTAINING CHAIN COMPOUND, PREPARATION METHOD, COMPOSITION INCLUDING SAME, AND APPLICATION

Resumen de: WO2026002273A1

Disclosed are a nitrogen-containing chain compound, a preparation method, a composition including same, and an application. Specifically, provided are a nitrogen-containing chain compound as shown in formula (I), or a pharmaceutically acceptable salt thereof. An LNP preparation prepared by using the nitrogen-containing chain compound has a relatively uniform nanoparticle size, a high encapsulation efficiency, and high in vivo expression activity.

一种包载异鼠李素的肉苁蓉来源外泌体及制备方法和应用

Resumen de: CN121243112A

本发明属于生物制药技术领域，具体涉及一种包载异鼠李素的肉苁蓉来源外泌体及制备方法和应用。本发明提供了一种负载异鼠李素的肉苁蓉外泌体（ISO@CD），以强化对氧化应激与线粒体功能的调控，协同增强DMED治疗效果。

一种“靶-药”自适转变交联自组装纳米平台及其制备方法和应用

Resumen de: CN121243110A

本发明属于药物递送系统构建领域，具体涉及一种“靶‑药”自适转变交联自组装纳米平台及其制备方法和应用。本发明创造性的将阿霉素作为自身口服递送的载体和靶向配体，实现了肿瘤部位的特异性靶向和治疗作用。通过特定的交联材料以二硫键交联将盐酸阿霉素稳定自组装，并使其亲水端糖环锚定在纳米粒表面，通过识别肠上皮细胞顶侧膜上高表达的SGLT1、OCTN2和基底侧的GLUT2，脑微血管内皮细胞和胶质瘤细胞表面的GLUT1从而跨越肠上皮细胞屏障和血脑屏障。该纳米粒不仅显著提高了阿霉素的口服生物利用度，且在脑部有高效的蓄积作用，进一步在高GSH环境下，断裂二硫键，释放阿霉素，实现了安全高效的抗肿瘤作用。

一种基于基因工程化细菌外膜囊泡-脂质体融合的超声响应性纳米颗粒及其制备方法和应用

Resumen de: CN121243375A

本发明属于生物医药技术领域，具体公开了一种基于基因工程化细菌外膜囊泡‑脂质体融合的超声响应性纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒OL@Ce6可通过三重协同机制突破肿瘤免疫治疗瓶颈：(1)免疫靶向强化：融合外壳中OMVs富含的PAMPs可被肿瘤微环境中抗原呈递细胞高效识别，显著提升肿瘤抗原递呈效率；(2)智能免疫调控：内核缓释的GM‑CSF强力募集DCs至肿瘤微环境并促进其成熟，建立持续性免疫应答枢纽；(3)声动力‑免疫协同：脂质双分子层中嵌入的声敏剂在超声辐照下爆发ROS，精准诱导肿瘤细胞ICD并释放DAMPs，激活细胞毒性T淋巴细胞深度浸润，形成抗肿瘤免疫正反馈循环。

一种用于治疗肺纤维化的纳米制剂及其制备方法、应用

Resumen de: CN121243128A

本发明公开了一种用于治疗肺纤维化的纳米制剂及其制备方法，属于生物医药技术领域。该纳米制剂为双纳米粒制剂，包括靶向远端气道上皮细胞的纳米粒A和靶向肌成纤维细胞的纳米粒B；所述纳米粒A由PLGA‑PEG、PLGA‑PEG‑HA和notch抑制剂制成；所述纳米粒B由PLGA‑PEG、PLGA‑PEG‑Mal、靶向肌成纤维细胞的肽和Hedgehog抑制剂制成。本发明的纳米制剂通过双纳米粒共同调控气道祖细胞向肺泡谱系分化，从而实现肺纤维化的治疗。

一种钴酸钙压电声敏剂的制备方法及其应用

Resumen de: CN121243380A

本发明公开一种钴酸钙压电声敏剂的制备方法及其在肿瘤治疗中的应用。以硝酸钙、硝酸钴为原料，溶于柠檬酸水溶液并加2%PEG形成前驱液，经80℃水解缩合得溶胶、陈化得凝胶，120℃干燥12小时后800℃煅烧2小时制钴酸钙纳米颗粒，再经PVP表面修饰得钴酸钙压电声敏剂。该声敏剂生物相容性与稳定性良好，具优异压电响应，超声下可形成内置电场，促进电子‑空穴对的分离并抑制其快速复合，提高活性氧产率，可用于肿瘤声动力治疗。其制备装置简易、操作简单、周期快，利于量产，为肿瘤声动力治疗提供新型高效纳米材料平台。

一种普鲁士蓝肉桂醛纳米酶复合物及其制备方法和应用

Resumen de: CN121243410A

本发明公开了一种普鲁士蓝肉桂醛纳米酶复合物及其制备方法和应用，属于生物医药技术领域。该复合物由普鲁士蓝纳米颗粒通过共价键或物理吸附负载肉桂醛构成，具有pH响应释放特性、良好的稳定性及协同抗炎抗氧化活性。其制备方法简单、条件温和、易于规模化。实验表明，该复合物能显著改善溃疡性结肠炎小鼠的疾病症状，降低炎症因子水平，增强抗氧化能力，效果优于单一成分，具有良好的临床应用前景。

ETHER-CONTAINING NOVEL IONIZABLE LIPIDS AND THEIR USES THEREOF

Resumen de: WO2026006579A1

Compounds are provided having the following structure: (I), or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein Y, Q, R, Ri, R2, m, n and o are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. Formula (I).

LIPID NANOPARTICLE SPHERICAL NUCLEIC ACIDS FOR GENOME ENGINEERING

Resumen de: WO2026006618A1

Spherical nucleic acids (SNAs) are an attractive platform for therapeutic delivery due to their chemically tunable structures, biocompatibility, and ability to rapidly enter cells without transfection reagents. The present disclosure provides SNAs and strategies for delivering genome editor proteins into cells. Concurrent delivery of genome editor proteins and a single-guide RNA in an SNA platform allows for rapid entry into mammalian cells and effective genome modification.

IN PLANTA NANO-DELIVERY OF NUCLEIC ACIDS INTO WHEAT AND OTHER CEREAL CROP SEED

Resumen de: WO2026006565A1

A method of introducing a polynucleotide into wheat seed using nanoparticles, e.g., mesoporous silica nanoparticles or silica nanoparticles comprising a polynucleotide, e.g., a polynucleotide for use in gene editing, transgene insertion, upregulation of gene expression, or downregulation of gene expression.

ALDEHYDE DEHYDROGENASE 2 ENZYMES, ALCOHOL DEHYDROGENASE 1 ENZYMES, NUCLEIC ACIDS ENCODING ENZYMES, LIPID NANOPARTICLES, AND METHODS OF USE

Resumen de: WO2026006513A2

Alcohol dehydrogenase 1 enzymes, aldehyde dehydrogenase 2 enzymes, nucleic acids encoding alcohol dehydrogenase 1 enzymes and aldehyde dehydrogenase 2 enzymes, lipid nanoparticles, lipid nanoparticles comprising nucleic acids encapsulated therein, pharmaceutical compositions comprising lipid nanoparticles which comprise nucleic acids encapsulated therein are useful for treating alcohol-related conditions, such as alcohol poisoning.

BRAIN TARGETED METABOLIC INHIBITION OF CANCER STEM CELLS TO DESTROY THEIR STEMNESS INDUCED TUMORIGENICITY

Resumen de: WO2026006393A1

Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.

一种荧光示踪的靶向光热抗肿瘤纳米颗粒的制备方法

Resumen de: CN121243374A

本发明公开了一种荧光示踪的靶向光热抗肿瘤纳米颗粒的制备方法，包括如下步骤：步骤1、制备含铁钛酸钡纳米颗粒BaTiO3/Fe；步骤2、用聚乙烯亚胺包裹BaTiO3/Fe，得到含铁钛酸钡纳米颗粒BaTiO3/Fe‑PEI；步骤3、将叶酸、N‑羟基琥珀酰亚胺和二氯乙烷溶解于超纯水中，磁力搅拌，使用NaOH溶液调节pH值至10，得到混合溶液A，将BaTiO3/Fe‑PEI分散于混合溶液A，搅拌反应24h，得到反应液B，透析，离心分离出固体产物，洗涤，得到肿瘤靶向纳米颗粒BaTiO3/Fe‑PEI‑FA；步骤4、将BaTiO3/Fe‑PEI‑FA分散于含有吲哚菁绿的磷酸盐缓冲液，避光反应12h，离心分离出固体产物，洗涤，冷冻干燥，得到荧光示踪的靶向光热抗肿瘤纳米颗粒BaTiO3/Fe‑PEI‑FA/ICG，具有良好的肿瘤靶向性和成像可视性，能够在超声和磁共振双模式成像引导下协同治疗肿瘤。

百日咳mRNA疫苗

Resumen de: CN121243358A

本发明提供了一种百日咳mRNA疫苗，所述百日咳mRNA疫苗包含一个或多个mRNA分子，所述mRNA分子编码的抗原包括：百日咳毒素，丝状血凝素；以及，百日咳黏附素。在一些情况中，所述mRNA分子编码的抗原还包括菌毛蛋白2和菌毛蛋白3。本发明通过gC180‑mRNA和FHA456‑mRNA疫苗为基础，配伍增加PRN‑mRNA的三组分百日咳mRNA疫苗，或配伍增加PRN和Fim2/3的五组分百日咳mRNA疫苗提高了百日咳mRNA疫苗的保护效果。

一种脐血间充质干细胞来源外泌体的纳米胶囊化方法

Resumen de: CN121243113A

本发明公开了一种脐血间充质干细胞来源外泌体的纳米胶囊化方法，具体涉及生物药品制造技术领域。首先从脐带血中分离、培养间充质干细胞并收集其分泌的外泌体；随后将外泌体悬浮液与特定分子量及脱乙酰度的壳聚糖溶液混合，再按比例加入海藻酸钠溶液，通过静电相互作用初步形成纳米胶囊；最后引入钙离子进行离子交联固化，经洗涤收集后得到稳定的纳米胶囊产品。本发明采用壳聚糖与海藻酸钠天然多糖复合体系，在温和的水相环境中通过简单的混合、滴加、交联三步核心工艺完成封装。本发明不仅工艺流程简便、重现性好、易于标准化规模化生产，而且能有效保护外泌体的天然生物活性与结构完整性。

基于NIR-II影像的多肽自组装纳米诊疗制剂及其制备方法

Nº publicación: CN121248636A 02/01/2026

Solicitante:

山西医科大学第一医院

Resumen de: CN121248636A

本发明公开了一种基于NIR‑II影像的多肽自组装纳米诊疗制剂及其制备方法，是制备一种全新的基于硒代二唑结构的聚集诱导发射发光体TPA‑Se，以其作为荧光探针，结合线粒体靶向前药LND‑1‑PEG‑24，包覆免疫细胞膜构建的影像导航‑免疫治疗‑肿瘤微环境重塑协同纳米体系。本发明不仅实现了制剂的肿瘤部位特异性靶向富集和精确生物成像，还能在肿瘤区域实现化疗药物靶向释放加速肿瘤细胞焦亡，同步实现光热治疗物理杀伤效应和化学治疗生物杀伤效应，为实现精确成像引导的显著杀伤肿瘤细胞及促进肿瘤细胞焦亡提供了新的方案。